Three firms that will revolutionise healthcare

Professional investor Paul Major of the BB Healthcare Trust selects three promising medical stocks to buy now.

Each week, a professional investor tells us where he'd put his money. This week: Paul Major of the BB Healthcare Trust selects three promising medical stocks.

The pace of medical breakthroughs has continued to accelerate, fuelled by a combination of technological developments and advanced treatments. Technology is not only helping to develop new cures, but also offers the potential substantially to lower the cost of healthcare for patients and providers.

There is understandably a focus on the price of innovative medicines. However, the proportion of healthcare expense accounted for by drug costs (less than 10%) has remained broadly stable over time. Cost inflation in the other 90% is less visible, but nonetheless important if we are to address the affordability crisis in healthcare.

The coming years will see the widespread adoption of novel technologies that offer the potential not only to improve care, but also to help avoid substantial future healthcare costs that our traditional delivery model makes inevitable.

How should an investor address this new opportunity? We think that an unconstrained "best-ideas" approach can offer a portfolio that is diversified in its exposure to these new opportunities, but also focused in terms of the number of holdings to offer a high level of operational gearing into the healthcare transformation story.

See your doctor from home

Teladoc (NYSE: TDOC) is a telemedicine provider offering patients a range of services to access medical advice, diagnostic services and prescriptions remotely. We are all aware of the increasing demands on GPs' time and the costs associated with unnecessary visits to hospitals. Teledoc offers lower cost, more convenient interactions with healthcare professionals and matches doctors' time with patients' needs truly a revolution at the frontline of care.

A nudge to visit the doctor

New medicines offering improved safety, efficacy and convenience have revolutionised the treatment of many diseases, such as the longer-acting insulins that allow diabetics better control of blood sugar throughout the day and into the night. Nonetheless, we still have high medical costs associated with the rare but serious episodes of very low blood sugar that patients must contend with. DexCom (Nasdaq: DXCM) develops and distributes discreet wearable monitors, which are an angel on the patient's shoulder, keeping them aware of their blood sugar and forewarning of potential dangerous events well ahead of time, saving money and improving outcomes.

A cancer detector

As we manage chronic diseases better, it is inevitable that cancer will claim more lives. The issue here is less the absence of potentially curative drugs than sufficient warning of this insidious killer's presence to allow early action. However, we have seen rapid progress in identifying the genetic fingerprints of the cellular changes that lead to cancer and, ultimately, routine screening for these markers will be available. If you can detect cancer before it spreads, outcomes are greatly improved. Products by Illumina (Nasdaq: ILMN) industrialise DNA screening, making it both rapid and cheap.

Recommended

Six high-yielding funds for income investors to buy now
Share tips

Six high-yielding funds for income investors to buy now

Rising interest rates are starting to make many popular income funds look less than attractive. Here, David Stevenson picks six that should weather th…
24 May 2022
Amazon’s shares have fallen hard – value investors should take note
Share tips

Amazon’s shares have fallen hard – value investors should take note

Investors have dumped Amazon shares as post-pandemic life returns to normal. But it still has plenty of competitive advantages, says Russell Hargreave…
23 May 2022
Three high-yielding FTSE 250 dividend stocks I’d invest in right now
Share tips

Three high-yielding FTSE 250 dividend stocks I’d invest in right now

The average FTSE 250 dividend yield is around 2.4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income inves…
23 May 2022
JD Sports will get back on track – here's how to play it
Trading

JD Sports will get back on track – here's how to play it

Sportswear retailer JD Sports was a profitable trade in 2019 and is worth watching again, says Matthew Partridge.
23 May 2022

Most Popular

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Barry Norris: we’re already in the 1970s. Here’s how to invest
Investment strategy

Barry Norris: we’re already in the 1970s. Here’s how to invest

Merryn talks to Barry Norris of Argonaut capital about the parallels between now and the 1970s; the transition to “green” energy; and the one sector w…
19 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022